Kautilya

A DNA vaccine carries into the body the genetic code for that part of a virus that triggers the immune system of the body. The message is decoded using the host cell’s own machinery to produce that antigen and stimulate the immune system. This ensures that later on when an actual infection occurs and the SARS-CoV2 enters the body, the immune system is already prepped to recognise it and knows what are the most effective ways to fight it.

Weinnovate Biosolutions was supported by CAWACH (Centre for Augmenting War with COVID-19 Health Crisis) 2020 grant from the National Science and Technology Entrepreneurship Development Board (NSTEDB) under the Department of Science and Technology (DST) and the project was incubated at Entrepreneurship Development Centre, Pune.

Council of Scientific & Industrial Research (CSIR), and Laxai Life Sciences Pvt. Ltd., Hyderabad, have been given the regulatory approval by the Drugs Controller General of India (DCGI) to undertake a two-arm phase-II clinical trial to assess the safety and efficacy of the drug Colchicine in the improvement of clinical outcomes during the treatment of COVID-19 patients. The partner CSIR institutes in this important clinical trial are the CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad and CSIR-Indian Institute of Integrative Medicine (IIIM), Jammu.